Research Progress of TACE Combined with Sorafenib in the Treatment of HCC
Abstract: 原发性肝癌(Hepatocellular carcinoma, HCC)起病隐匿，虽然手术治疗是首选，但患者因出现临床症状而就医时大多已进入中晚期，选择单纯的手术治疗不能达到预期的目的。针对这部分患者，肝动脉化疗栓塞术(transcatheter arterial chemoembolization, TACE)已成为首选。然而，采用此治疗方式，虽然能一定程度上缓解病情，但治疗效果有限。多项研究表明采用TACE联合索拉非尼的治疗方法，可以使中晚期原发性肝癌患者获益颇多，本文参考相关资料，探讨TACE联合索拉非尼治疗原发性肝癌的相关研究进展。 Hepatocellular carcinoma (HCC) has an insidious onset. Although surgical treatment is the first choice, most of the patients have entered the middle and advanced stages when they seek medical attention due to clinical symptoms, and surgical treatment alone cannot achieve the expected goals. For these patients, transcatheter arterial chemoembolization (TACE) has become the first choice. Although this treatment method can relieve the condition to a certain extent, the treatment effect is limited. A number of studies have shown that the use of TACE combined with sorafenib can benefit patients with advanced Hepatocellular carcinoma. This article refers to related materials to discuss the research progress of TACE combined with sorafenib in the treatment of Hepatocellular carcinoma.
Click here to see the statistics on "Asian Case Reports in Oncology" .